OOIR: Observatory of International Research

Papers

(The H4-Index of mAbs is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	286
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	206
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	109
BERT2DAb: a pre-trained model for antibody representation based on amino acid sequences and 2D-structure	83
Correction	80
Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer	77
Antibody-mediated degradation of 4R-tau restores mitochondrial membrane polarization in human induced pluripotent stem cell-derived neurons with the MAPT 10+16 mutation	68
Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains	59
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG ₁ antibodies	56
Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody	54
Charge heterogeneity of therapeutic monoclonal antibodies by different cIEF systems: views on the current situation	54
Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions	52
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	43
Modulation of the high concentration viscosity of IgG ₁ antibodies using clinically validated Fc mutations	40
CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody	39
Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age	36
Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches	36
Correlated analytical and functional evaluation of higher order structure perturbations from oxidation of NISTmAb	34
Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice	34
Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C _H 1-C _λ interfac	32
Determining the affinities of high-affinity antibodies using KinExA and surface plasmon resonance	32
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework	31
Efficient production of bispecific antibody by FAST-Ig ^TM and its application to NXT007 for the treatment of hemophilia A	31
Combinatorial Fc modifications for complementary antibody functionality	30
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity	29

Targeting γc family cytokines with biologics: current status and future prospects	29
Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4 ⁺ T cell interl	28